Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-02-14
2006-02-14
Weber, Jon (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S809000, C530S308000, C530S324000
Reexamination Certificate
active
06998387
ABSTRACT:
A composition including a compound which binds to a receptor for glucagon-like peptide-1 and a pharmaceutical carrier. The amount of the compound present is effective to control appetite in a human. Also disclosed is a method for controlling appetite and for reducing food intake in a human by administering to the human a composition comprising a compound which binds to a receptor for glucagon-like peptide-1 and a pharmaceutical carrier.
REFERENCES:
patent: 5120712 (1992-06-01), Habener
patent: 5631224 (1997-05-01), Efendic et al.
patent: 6191102 (2001-02-01), DiMarchi et al.
patent: 2003/0232754 (2003-12-01), Holst et al.
patent: WO 97/31943 (1997-09-01), None
patent: WO 97/31943 (1997-09-01), None
patent: WO 98/19698 (1998-05-01), None
patent: WO 98/30231 (1998-07-01), None
patent: WO 98/20895 (1999-05-01), None
Navarro et al., Journal Of Neurochemistry, vol. 67, No. 5, pp. 1982-1991, 1996.
Turton et al., (Nature, vol. 379, pp, 69-72, Jan. 4, 1996.
Furuse et al., Brain research, vol. 755, pp. 167-169, 1997.
Furuse et al. Effects of Various N-terminal Fragments of Glucagon-Like Peptide-1(7-36) on Food Intake in the Neonatal Chick. Brain Research. 1998, vol. 807, pp. 214-217, see entire document.
Turton et al. A Role for Glucagon-Like Peptide 1 in the Central Regulation of Feeding. Nature. Jan. 4, 1996, vol. 379, pp. 69-72, see entire document.
Navarro et al. Colocalization of Glucagon-Like Peptide-1 (GLP-1) Receptors, Glucose Transporter GLUT-2, and Glucokinase mRNAs in Rat Hypothalamic Cells: Evidence for a Role of GLP-1 Receptor Agonists as inhibitory Signal for Food and Water Intake. Journal of Neurochemistry, 1996, vol. 67, No. 5, pp. 1982-1991, especially pp. 1982-1983 and 1988-1990.
Furuse et al. Intracerebroventricular Injection of Mammalian and Chicken Glucagon-Like Peptide-1 Inhibits Food Intake of the Neonatal Chick. Brain Research. 1997, vol. 755, pp. 167-169, see entire document.
Merran et al. Repeated Intracerebroventricular Administration of Glucagon-Like Peptide-1 (7-36) Amide or Exendin-(9-39) Alters Body Weight in the Rat. Endocrinology. 1999, vol. 140, No. 1, pp. 244-250, especially pp. 244 and 249.
Naslund et al. Glucagon-Like Peptide-1 Increases the Period of Postprandial Safety and Slows Gastric Emptying in the Obese Men. Am. J. Clin. Nutr. 1998, vol. 68, pp. 525-530, especially pp. 525 and 528.
Gutzwiller et al. Glucagon-Like Peptide-1: A Potent Regulator of Food Intake in Humans. Gut. 1999, vol. 44, pp. 81-86, especially pp. 81, and 84-85.
Billington, et al., “Appetite regulation: Shedding new light on obesity,” Dispatch, Current Biology 1996, vol. 6 No. 8:920-923.
Beglinger Christoph
Coolidge Thomas R.
Goke Burkhard
Amylin Pharmaceuticals Inc.
Arnold & Porter LLP
Mohamed Abdel A.
Weber Jon
LandOfFree
Human appetite control by glucagon-like peptide receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human appetite control by glucagon-like peptide receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human appetite control by glucagon-like peptide receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3638059